Everolimus in Breast Cancer: The Role of the Pharmacist

Annals of Pharmacotherapy

Volumn 48, Issue 9, 2014, Pages 1194-1201

  Dorris, John R ^a   Jones, Suzanne ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

breast cancer; everolimus; pharmacist

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EVEROLIMUS; EXEMESTANE; GAMMA GLUTAMYLTRANSFERASE; MAMMALIAN TARGET OF RAPAMYCIN; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; DRUG SAFETY; HUMAN; META ANALYSIS; PHARMACIST; PHARMACY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84905466715     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014542415     Document Type: Review

References (38)

1. Breast Cancer Facts and Figures 2011-2012. Atlanta, GA: American Cancer Society; 2011:.
2. Carey LAUpToDate. Hayes DFDizon DS, ed. Waltham, MA: Up-to-Date; 2012:.
3. Jemal A,Bray F,Center MM, et al.Global cancer statistics, 2011.CA Cancer J Clin. 2011;61:69-90.
4. Villarreal-Garza C,Cortes J,Andre F,Verma S.mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.Ann Oncol. 2012;23:2526-2535.
5. Efeyan A,Sabatini DM.mTOR and cancer: many loops in one pathway.Curr Opin Cell Biol. 2010;22:169-176.
6. Yamnik RL,Holz MK.mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation.FEBS Lett. 2010;584:124-128.
7. Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation.Cell. 2011;144:646-674.
8. Margariti N,Fox SB,Bottini A,Generali D."Overcoming breast cancer drug resistance with mTOR inhibitors": could it be a myth or a real possibility in the short-term future?.Breast Cancer Res Treat. 2011;128:599-606.
9. Shojaei S,Gardaneh M,Shamabadi AR.Target points in trastuzumab resistance.Int J Breast Cancer. 2012;2012:761917.
10. Shtivelband MI.Everolimus in hormone receptor-positive advanced breast cancer: targeting receptor-based mechanisms of resistance.Breast. 2013;22:405-410.
11. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014:.
12. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012:.
13. US National Institutes of Health. ClinicalTrials.gov Web site. http://clinicaltrials.gov. Accessed October 31, 2012.
14. Smith IE,Dowsett M.Aromatase inhibitors in breast cancer.N Engl J Med. 2003;348:2431-2442.
15. Baselga J,Campone M,Piccart M, et al.Everolimus in post-menopausal hormone receptor positive advanced breast cancer.N Engl J Med. 2012;366:520-529.
16. Yardley DA,Noguchi S,Pritchard KI, et al.Everolimus plus exemestane in postmenopausal patients with HR breast cancer: BOLERO-2 final progression-free survival analysis.Adv Ther. 2013;30:870-884.
17. Baselga J,Semiglazov V,van Dam P, et al.Phase II randomized study of neoadjuvant everolimus plus letrozole in patients with estrogen receptor-positive breast cancer.J Clin Oncol. 2009;27:2630-2637.
18. Bachelot T,Bourgier C,Cropet C, et al.Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.J Clin Oncol. 2012;30:2718-2724.
19. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), version 3.0, August 9, 2006. Bethesda, MD: Cancer Therapy Evaluation Program. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed June 19, 2014.
20. Pritchard KI,Burris HA,Ito Y, et al.Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.Clin Breast Cancer. 2013;13:421-432.
21. Burris HA,Lebrun F,Rugo HS, et al.Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.Cancer. 2013;119:1908-1915.
22. Schwartz RN,Eng KJ,Frieze DA, et al.NCCN Task Force report: specialty pharmacy.J Natl Compr Canc Netw. 2010;8:S1-S12.
23. Zolnierek KBH,DiMatteo MR.Physician communication and patient adherence to treatment: a meta-analysis.Med Care. 2009;47:826-834.
24. Hohneker J,Shah-Mehta S,Brandt PS.Perspectives on adherence and persistence with oral medications for cancer treatment.J Oncol Pract. 2011;7:65-67.
25. Cauley DH.Newly approved mTOR inhibitors for the treatment of metastatic renal cell carcinoma.US Pharm. 2009;34:HS20-HS26.
26. Barnett CM.Everolimus: targeted therapy on the horizon for the treatment of breast cancer.Pharmacotherapy. 2012;32:383-396.
27. Porta C,Osanto S,Ravaud A, et al.Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.Eur J Cancer. 2011;47:1287-1298.
28. Albiges L,Chamming's F,Duelos B, et al.Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.Ann Oncol. 2012;23:1945-1953.
29. Busardy NL,Farooki A,Dowlati A, et al.Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.J Clin Oncol. 2012;30:2919-2928.
30. HornJRHanstenPD. Get to know an enzyme: CYP3A4. http://www.hanstenandhorn.com/hh-article09-08.pdf. Accessed June 5, 2012.
31. Longo DLHarrison's Principles of Internal Medicine. 18th ed.New York, NY: McGraw-Hill; 2012:chap 84.Fauci ASKasper DLJameson JLLongo DLHauser SL, ed. New York, NY: McGraw-Hill; 2012:84.
32. Grabowsky JA.Drug interactions and the pharmacist: focus on everolimus.Ann Pharmacother. 2013;47:1055-1063.
33. Peveling-Oberhag J,Zeuzem S,Yong WP, et al.Effect of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.Clin Ther. 2013;35:215-225.
34. O'Donnell A,Faivre S,Burris HA, et al.Phase I pharmacokinetic and pharmacodynamics study of the mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.J Clin Oncol. 2008;26:1588-1595.
35. Jiralerspong S,Palla SL,Giordano SH, et al.Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.J Clin Oncol. 2009;27:3297-3302.
36. Martin M,Marais R.Metformin: a diabetes drug for cancer, or a cancer drug for diabetics?.J Clin Oncol. 2012;30:2698-2700.
37. Wild S,Roglic G,Green A, et al.Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.Diabetes Care. 2004;27:1047-1053.
38. Kiel PJ,McCord AD.Pharmacist impact on clinical outcomes in a diabetes disease management program via collaborative practice.Ann Pharmacother. 2005;39:1828-1832.